Gedivumab

Gedivumab (MHAA4549A; RG7745), a human monoclonal antibody, exhibits high specificity in targeting the influenza A virus (IAV) by binding to the highly conserved stem region of the IAV hemagglutinin protein. This interaction inhibits hemagglutinin maturation and blocks hemagglutinin-mediated membrane fusion within the intranucleosome, making Gedivumab useful for studies on IAV infection disease [1].